行情

ADMP

ADMP

Adamis制药
NASDAQ

实时行情|Nasdaq Last Sale

0.9201
-0.0299
-3.15%
交易中 13:01 11/14 EST
开盘
0.9282
昨收
0.9500
最高
0.9399
最低
0.9000
成交量
51.73万
成交额
--
52周最高
3.290
52周最低
0.4800
市值
5,652.92万
市盈率(TTM)
-1.1062
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ADMP 新闻

  • Adamis Pharmaceuticals Corp (ADMP) CEO Dennis Carlo on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.1天前
  • Adamis Pharmaceuticals EPS misses by $0.02, misses on revenue
  • seekingalpha.1天前
  • Adamis Pharmaceuticals (ADMP) Reports Q3 Loss, Misses Revenue Estimates
  • Zacks.1天前
  • Adamis Pharmaceuticals Q3 Sales $5.9M Miss $6.37M Estimate; Cash And Cash Equivalents At End Of Q3 $12.1M
  • Benzinga.1天前

更多

所属板块

制药
-0.56%
制药与医学研究
-0.45%

热门股票

名称
价格
涨跌幅

ADMP 简况

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company's lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.
展开

Webull提供Adamis Pharmaceuticals Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。